STK-012 shows promise in resistant lung cancer biology, but can Synthekine deliver in Phase 2?
Synthekine’s STK-012 showed encouraging AACR 2026 data in resistant NSCLC. Read what the results could mean for frontline lung cancer treatment.
Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?
Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.